True Wealth Design’s Protara Therapeutics TARA Stock Holding History

True Wealth Design’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$199	Buy	52 +28	+117%	+$133	﹤0.01%	2447
2026 Q1	$126	Buy	+24	New	+$142	﹤0.01%	2429

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

True Wealth Design's TARA Position: Q2 2026 in Review

True Wealth Design increased its Protara Therapeutics (TARA) stake by 117% in Q2 2026, buying an estimated $133 and bringing the position to 52 shares worth $199. The position accounts for ﹤0.01% of the portfolio, ranked #2447.

True Wealth Design first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

True Wealth Design held 52 shares of Protara Therapeutics worth $199 as of Q2 2026.
True Wealth Design bought 28 Protara Therapeutics shares in Q2 2026, an estimated $133.
Protara Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2447 holding.
True Wealth Design first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.